retatrutide parkinson's disease trial nct New Drug Trials for Parkinson's Insights into Parkinson's Disease Trials
Description
Women, especially, should learn about their bone health and get a baseline bone mineral density test, called a DXA scan, before starting a GLP-1
Clinical trial data show that gastrointestinal adverse effectsincluding nausea, vomiting, diarrhea, and abdominal discomfortoccur in 20-50% of patients initiating GLP-1 therapy, with rates varying by specific agent and dose
Facials : We offer several different types of facials to help each patient rejuvenate their skin
Most patients enjoy results for up to two years, with improvements developing over several months as collagen increases
The Three-Receptor Mechanism GLP-1 receptor activation produces the appetite suppression most people associate with these medications
Lastly, obesity is a risk factor for venous thromboembolism (VTE)
